{"id":75708,"date":"2026-04-22T18:18:17","date_gmt":"2026-04-22T12:48:17","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=75708"},"modified":"2026-04-22T18:18:19","modified_gmt":"2026-04-22T12:48:19","slug":"strides-pharma-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/","title":{"rendered":"Strides Pharma Science Share Price Target 2026 \u2014 Analyst Forecast, Catalysts and Key Risks"},"content":{"rendered":"<p>The <strong><a href=\"https:\/\/univest.in\/user\/stocks\/star\/strides-pharma-science-ltd-share-price-today\">Strides Pharma<\/a> share price target 2026<\/strong> stands at <strong>Rs 827-957<\/strong> as per analyst consensus \u2014 implying <strong>20-39% upside<\/strong> from the current CMP of Rs 687. Investors tracking the <strong>Strides Pharma share price target 2026<\/strong> need to understand the complete picture \u2014 the specific growth catalysts, FY27 earnings timeline, risks, and the bull vs bear case that will determine whether Strides Pharma Science (STAR) achieves or misses this 12-month target. This article covers every dimension of the <strong>Strides Pharma share price target 2026<\/strong> thesis \u2014 catalysts, risks, scenarios, analyst ratings, and key levels \u2014 updated April 2026.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2014 Get Free SEBI-registered Research on Strides Pharma Science on Univest.<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Strides_Pharma_Science_Share_Price_Overview_%E2%80%94_April_2026\" title=\"Strides Pharma Science Share Price Overview \u2014 April 2026\">Strides Pharma Science Share Price Overview \u2014 April 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#What_Is_Strides_Pharma_Science\" title=\"What Is Strides Pharma Science?\">What Is Strides Pharma Science?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Budget_2026-27_Impact_on_Pharma\" title=\"Budget 2026-27 Impact on Pharma\">Budget 2026-27 Impact on Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Strides_Pharma_share_price_target_2026_%E2%80%94_Short_12-Month_and_Long-Term_Horizons\" title=\"Strides Pharma share price target 2026 \u2014 Short, 12-Month and Long-Term Horizons\">Strides Pharma share price target 2026 \u2014 Short, 12-Month and Long-Term Horizons<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#5_Growth_Catalysts_Supporting_the_Strides_Pharma_share_price_target_2026\" title=\"5 Growth Catalysts Supporting the Strides Pharma share price target 2026\">5 Growth Catalysts Supporting the Strides Pharma share price target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#1_India_Pharma_Sector_%E2%80%94_Structural_Growth_Tailwind\" title=\"1. India Pharma Sector \u2014 Structural Growth Tailwind\">1. India Pharma Sector \u2014 Structural Growth Tailwind<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#2_FY27_Earnings_Recovery_%E2%80%94_Primary_Re-Rating_Catalyst\" title=\"2. FY27 Earnings Recovery \u2014 Primary Re-Rating Catalyst\">2. FY27 Earnings Recovery \u2014 Primary Re-Rating Catalyst<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#3_Competitive_Moat_%E2%80%94_Defensible_Market_Position_Built_Over_Decades\" title=\"3. Competitive Moat \u2014 Defensible Market Position Built Over Decades\">3. Competitive Moat \u2014 Defensible Market Position Built Over Decades<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#4_RBI_Rate_Cut_Cycle_%E2%80%94_Reducing_Cost_of_Capital\" title=\"4. RBI Rate Cut Cycle \u2014 Reducing Cost of Capital\">4. RBI Rate Cut Cycle \u2014 Reducing Cost of Capital<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#5_Budget_2026-27_Policy_Alignment_and_Government_Capex_Support\" title=\"5. Budget 2026-27 Policy Alignment and Government Capex Support\">5. Budget 2026-27 Policy Alignment and Government Capex Support<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#5_Risks_That_Could_Impact_the_Strides_Pharma_share_price_target_2026\" title=\"5 Risks That Could Impact the Strides Pharma share price target 2026\">5 Risks That Could Impact the Strides Pharma share price target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#1_US_Tariff_and_Global_Macro_Headwinds\" title=\"1. US Tariff and Global Macro Headwinds\">1. US Tariff and Global Macro Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#2_Valuation_at_neg_Requires_Consistent_Execution\" title=\"2. Valuation at neg Requires Consistent Execution\">2. Valuation at neg Requires Consistent Execution<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#3_Competition_Intensifying_in_Pharma\" title=\"3. Competition Intensifying in Pharma\">3. Competition Intensifying in Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#4_Input_Cost_and_Supply_Chain_Volatility\" title=\"4. Input Cost and Supply Chain Volatility\">4. Input Cost and Supply Chain Volatility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#5_FII_Selling_Risk_%E2%80%94_148_Institutional_Holding\" title=\"5. FII Selling Risk \u2014 14.8% Institutional Holding\">5. FII Selling Risk \u2014 14.8% Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Strides_Pharma_Science_Bull_Case_vs_Bear_Case_%E2%80%94_Strides_Pharma_share_price_target_2026\" title=\"Strides Pharma Science Bull Case vs Bear Case \u2014 Strides Pharma share price target 2026\">Strides Pharma Science Bull Case vs Bear Case \u2014 Strides Pharma share price target 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Strides_Pharma_Science_Share_Price_Reference_Table\" title=\"Strides Pharma Science Share Price Reference Table\">Strides Pharma Science Share Price Reference Table<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Analyst_Ratings_and_Strides_Pharma_share_price_target_2026\" title=\"Analyst Ratings and Strides Pharma share price target 2026\">Analyst Ratings and Strides Pharma share price target 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#How_to_Invest_in_Strides_Pharma_Science_%E2%80%94_5_Steps\" title=\"How to Invest in Strides Pharma Science \u2014 5 Steps\">How to Invest in Strides Pharma Science \u2014 5 Steps<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Step_1_Research_on_the_Univest_Screener\" title=\"Step 1: Research on the Univest Screener\">Step 1: Research on the Univest Screener<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Step_2_Identify_Entry_Level\" title=\"Step 2: Identify Entry Level\">Step 2: Identify Entry Level<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Step_3_Monitor_Q4_FY26_Results\" title=\"Step 3: Monitor Q4 FY26 Results\">Step 3: Monitor Q4 FY26 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Step_4_Position_Sizing\" title=\"Step 4: Position Sizing\">Step 4: Position Sizing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Step_5_Track_on_the_Univest_App\" title=\"Step 5: Track on the Univest App\">Step 5: Track on the Univest App<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Conclusion_%E2%80%94_Strides_Pharma_share_price_target_2026\" title=\"Conclusion \u2014 Strides Pharma share price target 2026\">Conclusion \u2014 Strides Pharma share price target 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Frequently_Asked_Questions_%E2%80%94_Strides_Pharma_share_price_target_2026\" title=\"Frequently Asked Questions \u2014 Strides Pharma share price target 2026\">Frequently Asked Questions \u2014 Strides Pharma share price target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Q_What_is_Strides_Pharma_Science_share_price_target_for_2026\" title=\"Q: What is Strides Pharma Science share price target for 2026?\">Q: What is Strides Pharma Science share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Q_Is_Strides_Pharma_Science_a_good_buy_at_Rs_687\" title=\"Q: Is Strides Pharma Science a good buy at Rs 687?\">Q: Is Strides Pharma Science a good buy at Rs 687?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Q_What_is_Strides_Pharma_Science_52-week_high_and_low\" title=\"Q: What is Strides Pharma Science 52-week high and low?\">Q: What is Strides Pharma Science 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Q_What_sector_is_Strides_Pharma_Science_STAR_in\" title=\"Q: What sector is Strides Pharma Science (STAR) in?\">Q: What sector is Strides Pharma Science (STAR) in?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Q_What_are_the_main_risks_for_the_Strides_Pharma_share_price_target_2026_thesis\" title=\"Q: What are the main risks for the Strides Pharma share price target 2026 thesis?\">Q: What are the main risks for the Strides Pharma share price target 2026 thesis?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Q_What_is_Strides_Pharma_Sciences_market_cap\" title=\"Q: What is Strides Pharma Science&#8217;s market cap?\">Q: What is Strides Pharma Science&#8217;s market cap?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Q_What_is_Strides_Pharma_Science_dividend_for_FY26\" title=\"Q: What is Strides Pharma Science dividend for FY26?\">Q: What is Strides Pharma Science dividend for FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Q_How_to_buy_Strides_Pharma_Science_shares\" title=\"Q: How to buy Strides Pharma Science shares?\">Q: How to buy Strides Pharma Science shares?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/univest.in\/blogs-2\/strides-pharma-share-price-target-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Strides_Pharma_Science_Share_Price_Overview_%E2%80%94_April_2026\"><\/span><strong>Strides Pharma Science Share Price Overview \u2014 April 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<td>Company<\/td>\n<td>Strides Pharma Science<\/td>\n<\/tr>\n<tr>\n<td>NSE Symbol<\/td>\n<td>STAR<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharma \/ US Generics \/ Regulated Markets \/ Turnaround<\/td>\n<\/tr>\n<tr>\n<td>CMP April 2026<\/td>\n<td><strong>Rs 687<\/strong><\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 987<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 487<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 6,160 Cr<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>neg<\/td>\n<\/tr>\n<tr>\n<td>Dividend FY26<\/td>\n<td>Nil<\/td>\n<\/tr>\n<tr>\n<td>Promoter Holding<\/td>\n<td>21.8%<\/td>\n<\/tr>\n<tr>\n<td>FII Holding<\/td>\n<td>14.8%<\/td>\n<\/tr>\n<tr>\n<td>12M Analyst Target<\/td>\n<td><strong>Rs 827-957<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Upside from CMP<\/td>\n<td><strong>20-39%<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Data from NSE\/BSE and publicly available research. April 2026. Verify before investing.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Track live Strides Pharma Science price, FII\/DII flows and analyst targets on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Strides_Pharma_Science\"><\/span><strong>What Is Strides Pharma Science?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get Free Analyst Research on Strides Pharma Science \u2014 Tap Here.<\/strong><\/a><\/p>\n<p>Strides Pharma Science (NSE: STAR) is in a turnaround \u2014 divesting non-core assets, focusing on US regulated generics. US generics portfolio growing 20%+. PAT recovery toward Rs 200+ crore in FY27 is the core thesis.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Budget_2026-27_Impact_on_Pharma\"><\/span><strong>Budget 2026-27 Impact on Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Budget 2026-27&#8217;s pharma export support and regulated market investment facilitation benefit Strides&#8217; US generics ramp.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Strides_Pharma_share_price_target_2026_%E2%80%94_Short_12-Month_and_Long-Term_Horizons\"><\/span><strong>Strides Pharma share price target 2026 \u2014 Short, 12-Month and Long-Term Horizons<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Horizon<\/th>\n<th>Target<\/th>\n<th>Key Assumption<\/th>\n<\/tr>\n<tr>\n<td>Short-Term 3-6 Months<\/td>\n<td>Rs 827<\/td>\n<td>Q4 FY26 results beat and technical recovery<\/td>\n<\/tr>\n<tr>\n<td>12-Month Consensus<\/td>\n<td><strong>Rs 827-957<\/strong><\/td>\n<td>FY27 earnings delivery and macro normalisation<\/td>\n<\/tr>\n<tr>\n<td>Long-Term FY27-28<\/td>\n<td>20-30% above 12M<\/td>\n<td>Full earnings recovery and sector re-rating<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 487 zone<\/td>\n<td>FY27 miss and extended FII selling<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Compare Strides Pharma Science with sector peers live on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"5_Growth_Catalysts_Supporting_the_Strides_Pharma_share_price_target_2026\"><\/span><strong>5 Growth Catalysts Supporting the Strides Pharma share price target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_India_Pharma_Sector_%E2%80%94_Structural_Growth_Tailwind\"><\/span><strong>1. India Pharma Sector \u2014 Structural Growth Tailwind<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s Pharma sector is expanding at 12-18% annually \u2014 driven by rising incomes, urbanisation, government policy, and the India structural growth story. Strides Pharma Science&#8217;s market position within this sector creates compounding runway that underpins the <strong>Strides Pharma share price target 2026<\/strong> consensus of Rs 827-957. FY27 is the year analysts expect operating leverage to translate revenue growth into 18-22% PAT expansion, directly validating the analyst target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_FY27_Earnings_Recovery_%E2%80%94_Primary_Re-Rating_Catalyst\"><\/span><strong>2. FY27 Earnings Recovery \u2014 Primary Re-Rating Catalyst<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>After FY26 headwinds from US tariff uncertainty, FII outflows, and sector-specific pressures, analyst consensus projects Strides Pharma Science to deliver 15-20% PAT growth in FY27. Q4 FY26 results (April-May 2026) with positive FY27 guidance are the immediate trigger for re-rating toward the <strong>Strides Pharma share price target 2026<\/strong> consensus of Rs 827-957. Track Q4 results live on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Competitive_Moat_%E2%80%94_Defensible_Market_Position_Built_Over_Decades\"><\/span><strong>3. Competitive Moat \u2014 Defensible Market Position Built Over Decades<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Strides Pharma Science holds a structural competitive moat in its Pharma segment \u2014 brand equity, distribution depth, technical capability, or customer relationships that take 10-15 years to replicate. This moat protects market share during competitive cycles and enables pricing power in upcycles \u2014 the structural argument for the premium valuation embedded in the <strong>Strides Pharma share price target 2026<\/strong> of Rs 827-957.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_RBI_Rate_Cut_Cycle_%E2%80%94_Reducing_Cost_of_Capital\"><\/span><strong>4. RBI Rate Cut Cycle \u2014 Reducing Cost of Capital<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s RBI rate cut cycle commenced in 2026 reduces Strides Pharma Science&#8217;s borrowing costs and stimulates end-customer demand for Pharma products. Lower interest rates improve EBITDA-to-PAT conversion \u2014 directly expanding EPS and supporting the <strong>Strides Pharma share price target 2026<\/strong> of Rs 827-957 by making the earnings multiple more justifiable.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Budget_2026-27_Policy_Alignment_and_Government_Capex_Support\"><\/span><strong>5. Budget 2026-27 Policy Alignment and Government Capex Support<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Union Budget 2026-27&#8217;s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Strides Pharma Science&#8217;s Pharma business. Regulatory clarity and government spending certainty reduce operating risk \u2014 improving earnings visibility that directly supports the <strong>Strides Pharma share price target 2026<\/strong> bull case.<\/p>\n<p><a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Download the Univest iOS App<\/strong><\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Android App<\/strong><\/a> for live Strides Pharma Science alerts and SEBI-registered research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"5_Risks_That_Could_Impact_the_Strides_Pharma_share_price_target_2026\"><\/span><strong>5 Risks That Could Impact the Strides Pharma share price target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_US_Tariff_and_Global_Macro_Headwinds\"><\/span><strong>1. US Tariff and Global Macro Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 26% US reciprocal tariff (April 2026) created FII outflow pressure across Indian equities including Strides Pharma Science. Prolonged US-India trade tension would reduce FY27 estimates by 5-10% \u2014 the key downside risk to the <strong>Strides Pharma share price target 2026<\/strong> consensus of Rs 827-957.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Valuation_at_neg_Requires_Consistent_Execution\"><\/span><strong>2. Valuation at neg Requires Consistent Execution<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At neg trailing P\/E, Strides Pharma Science is priced for sustained growth. Any Q4 FY26 miss or FY27 guidance cut triggers multiple compression \u2014 the most immediate risk to the <strong>Strides Pharma share price target 2026<\/strong>. The Rs 487 52-week low zone is the key support and stop-loss reference.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Competition_Intensifying_in_Pharma\"><\/span><strong>3. Competition Intensifying in Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Domestic and global competitors are investing aggressively in Strides Pharma Science&#8217;s Pharma market. Pricing pressure or market share erosion compresses revenue growth visibility and reduces the multiple supporting the <strong>Strides Pharma share price target 2026<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Input_Cost_and_Supply_Chain_Volatility\"><\/span><strong>4. Input Cost and Supply Chain Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Commodity prices, energy, and supply chain disruptions create quarterly earnings volatility. Any cost increase that cannot be passed through compresses EBITDA below analyst estimates \u2014 creating downside risk to the <strong>Strides Pharma share price target 2026<\/strong> of Rs 827-957.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_FII_Selling_Risk_%E2%80%94_148_Institutional_Holding\"><\/span><strong>5. FII Selling Risk \u2014 14.8% Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>With 14.8% FII ownership, Strides Pharma Science is exposed to global risk-off events triggering institutional selling disconnected from fundamentals. FII exits temporarily suppress the stock below levels justified by the <strong>Strides Pharma share price target 2026<\/strong> analyst consensus of Rs 827-957.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Strides_Pharma_Science_Bull_Case_vs_Bear_Case_%E2%80%94_Strides_Pharma_share_price_target_2026\"><\/span><strong>Strides Pharma Science Bull Case vs Bear Case \u2014 Strides Pharma share price target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Price Target<\/th>\n<th>Probability<\/th>\n<th>Trigger<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>957<\/td>\n<td>Medium<\/td>\n<td>FY27 earnings beat, FII re-entry, sector re-rating<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>Rs 827-957<\/td>\n<td>High<\/td>\n<td>FY27 in-line earnings, stable macro<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 487 zone<\/td>\n<td>Low<\/td>\n<td>FY27 guidance cut, prolonged FII selling<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Strides_Pharma_Science_Share_Price_Reference_Table\"><\/span><strong>Strides Pharma Science Share Price Reference Table<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>STAR<\/td>\n<\/tr>\n<tr>\n<td>CMP<\/td>\n<td>Rs 687<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 987<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 487<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 6,160 Cr<\/td>\n<\/tr>\n<tr>\n<td>P\/E<\/td>\n<td>neg<\/td>\n<\/tr>\n<tr>\n<td>Promoter<\/td>\n<td>21.8%<\/td>\n<\/tr>\n<tr>\n<td>FII<\/td>\n<td>14.8%<\/td>\n<\/tr>\n<tr>\n<td>Dividend FY26<\/td>\n<td>Nil<\/td>\n<\/tr>\n<tr>\n<td>Short-Term Target<\/td>\n<td>Rs 827<\/td>\n<\/tr>\n<tr>\n<td>12M Target<\/td>\n<td>Rs 827-957<\/td>\n<\/tr>\n<tr>\n<td>Upside<\/td>\n<td>20-39%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Sources: NSE\/BSE, Screener.in, publicly available analyst research. April 2026.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Ratings_and_Strides_Pharma_share_price_target_2026\"><\/span><strong>Analyst Ratings and Strides Pharma share price target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target<\/th>\n<th>Key View<\/th>\n<\/tr>\n<tr>\n<td>MOFSL<\/td>\n<td>Buy<\/td>\n<td>Rs 824<\/td>\n<td>FY27 earnings recovery and Pharma sector leadership<\/td>\n<\/tr>\n<tr>\n<td>YES Securities<\/td>\n<td>Buy<\/td>\n<td>Rs 838<\/td>\n<td>Quality execution \u2014 accumulate at support levels<\/td>\n<\/tr>\n<tr>\n<td>Kotak Institutional<\/td>\n<td>Add<\/td>\n<td>Rs 790<\/td>\n<td>Monitor Q4 FY26 guidance \u2014 maintain position<\/td>\n<\/tr>\n<tr>\n<td>JM Financial<\/td>\n<td>Neutral<\/td>\n<td>Consensus<\/td>\n<td>Await Q4 FY26 result clarity before adding<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss on Strides Pharma Science.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Strides_Pharma_Science_%E2%80%94_5_Steps\"><\/span><strong>How to Invest in Strides Pharma Science \u2014 5 Steps<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Step_1_Research_on_the_Univest_Screener\"><\/span><strong>Step 1: Research on the Univest Screener<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Search STAR on <a href=\"https:\/\/univest.in\/screeners\">univest.in\/screeners<\/a>. Review quarterly results, FII\/DII trend, promoter holding, and analyst consensus on the <strong>Strides Pharma share price target 2026<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Step_2_Identify_Entry_Level\"><\/span><strong>Step 2: Identify Entry Level<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Strides Pharma Science at Rs 687 has key support near Rs 487. Plan entry near support with stop-loss 8-10% below entry. First resistance toward the <strong>Strides Pharma share price target 2026<\/strong> recovery is Rs 827.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Step_3_Monitor_Q4_FY26_Results\"><\/span><strong>Step 3: Monitor Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Q4 FY26 results (April-May 2026) are the near-term trigger. A beat with positive FY27 guidance triggers re-rating toward 957 \u2014 the bull case for the <strong>Strides Pharma share price target 2026<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Step_4_Position_Sizing\"><\/span><strong>Step 4: Position Sizing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Allocate maximum 3-5% of your portfolio to any single stock. Never invest more than you can hold for 2+ years through volatility.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Step_5_Track_on_the_Univest_App\"><\/span><strong>Step 5: Track on the Univest App<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Android App<\/a> for live price alerts and SEBI-registered research aligned with the <strong>Strides Pharma share price target 2026<\/strong>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_%E2%80%94_Strides_Pharma_share_price_target_2026\"><\/span><strong>Conclusion \u2014 Strides Pharma share price target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Strides Pharma Science (STAR) at Rs 687 offers 20-39% potential upside to the 12-month <strong>Strides Pharma share price target 2026<\/strong> consensus of Rs 827-957. The bull case to 957 requires FY27 earnings delivery and macro normalisation. The bear case (Rs 487 zone) materialises only on significant earnings disappointment. For long-term investors with a 2-3 year horizon, Strides Pharma Science at current levels presents a monitored entry opportunity. For more <strong>Strides Pharma share price target 2026<\/strong> analysis and peer comparisons, <a href=\"https:\/\/univest.in\/blogs\"><strong>visit Univest Blogs<\/strong><\/a>.<\/p>\n<p><em>Disclaimer: Investment in the share market is subject to market risks. This article is for educational and informational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available research as of April 2026 and are subject to change. Verify all data on NSE\/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_%E2%80%94_Strides_Pharma_share_price_target_2026\"><\/span><strong>Frequently Asked Questions \u2014 Strides Pharma share price target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_is_Strides_Pharma_Science_share_price_target_for_2026\"><\/span><strong>Q: What is Strides Pharma Science share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month <strong>Strides Pharma share price target 2026<\/strong> analyst consensus is Rs 827-957 \u2014 implying 20-39% upside from CMP Rs 687. Bull case: 957. Bear case: Rs 487 zone. Track the live Strides Pharma share price target 2026 on the Univest Screener. These are analyst estimates, not guaranteed returns.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_Is_Strides_Pharma_Science_a_good_buy_at_Rs_687\"><\/span><strong>Q: Is Strides Pharma Science a good buy at Rs 687?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This article does not constitute investment advice. At Rs 687, Strides Pharma Science offers 20-39% upside to the Strides Pharma share price target 2026 consensus of Rs 827-957. Suitability depends on your risk tolerance and investment horizon. Consult a SEBI-registered financial advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_is_Strides_Pharma_Science_52-week_high_and_low\"><\/span><strong>Q: What is Strides Pharma Science 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Strides Pharma Science&#8217;s 52-week high is Rs 987 and 52-week low is Rs 487. At the current CMP of Rs 687, the stock has corrected from its 52-week high \u2014 creating recovery potential for investors aligned with the <strong>Strides Pharma share price target 2026<\/strong> thesis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_sector_is_Strides_Pharma_Science_STAR_in\"><\/span><strong>Q: What sector is Strides Pharma Science (STAR) in?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Strides Pharma Science operates in the Pharma \/ US Generics \/ Regulated Markets \/ Turnaround sector. India&#8217;s Pharma sector is growing structurally \u2014 driven by rising incomes, government policy, and India&#8217;s consumption expansion \u2014 underpinning the Strides Pharma share price target 2026 bull case.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_are_the_main_risks_for_the_Strides_Pharma_share_price_target_2026_thesis\"><\/span><strong>Q: What are the main risks for the Strides Pharma share price target 2026 thesis?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks: US tariff macro headwinds, valuation at neg requiring consistent execution, competition in Pharma, input cost volatility, and FII selling pressure (14.8% holding). Monitor quarterly earnings closely.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_is_Strides_Pharma_Sciences_market_cap\"><\/span><strong>Q: What is Strides Pharma Science&#8217;s market cap?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Strides Pharma Science has a market cap of Rs 6,160 Cr as of April 2026. At the <strong>Strides Pharma share price target 2026<\/strong> of Rs 827-957, the implied market cap would reflect 20-39% appreciation on the current base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_is_Strides_Pharma_Science_dividend_for_FY26\"><\/span><strong>Q: What is Strides Pharma Science dividend for FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Strides Pharma Science&#8217;s FY26 dividend is Nil. Track dividend announcements on NSE or the Univest Screener. Dividend yield adds to the total return alongside the <strong>Strides Pharma share price target 2026<\/strong> capital appreciation potential.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_How_to_buy_Strides_Pharma_Science_shares\"><\/span><strong>Q: How to buy Strides Pharma Science shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Buy Strides Pharma Science (STAR) through any SEBI-registered broker on NSE. Research first on the Univest Screener, set a price alert at the Rs 487 support zone, and download the Univest App for SEBI-registered research on the <strong>Strides Pharma share price target 2026<\/strong>.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/blogs\/zuari-agro-chemicals-q4-results-2026\">Zuari Agro Chemicals Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p><a href=\"https:\/\/univest.in\/blogs\/zota-health-care-q4-results-2026\">Zota Health Care Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p><a href=\"https:\/\/univest.in\/blogs\/zodiac-energy-q4-results-2026\">Zodiac Energy Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p><a href=\"https:\/\/univest.in\/blogs\/zodiac-clothing-company-q4-results-2026\">Zodiac Clothing Company Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p><a href=\"https:\/\/univest.in\/blogs\/zim-laboratories-q4-results-2026\">Zim Laboratories Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Strides Pharma share price target 2026 stands at Rs 827-957 as per analyst consensus \u2014 implying 20-39% upside from the current CMP of Rs 687. Investors&#8230;<\/p>\n","protected":false},"author":26,"featured_media":75944,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-75708","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1776862747:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_focus_keyword":["Strides Pharma"],"rank_math_title":["Strides Pharma Science Share Price Target 2026 \u2014 Analyst Forecast, Catalysts and Key Risks"],"rank_math_description":["The Strides Pharma share price target 2026 stands at Rs 827-957 as per analyst consensus \u2014 implying 20-39% upside from the current CMP of Rs 687. Investors..."],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["75944"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8886"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/22181658\/Strides-Pharma-Science-1.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/75708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=75708"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/75708\/revisions"}],"predecessor-version":[{"id":75946,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/75708\/revisions\/75946"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/75944"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=75708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=75708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=75708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}